Viva In Vitro Diagnostics congratulates Dr. Pablo Pelegrín Vivancos on his international recognition as one of the world’s most highly cited Spanish scientists, according to the 2025 edition of the Highly Cited Researchers ranking published by Clarivate Analytics.
This list distinguishes the top 1% of researchers worldwide with the greatest global impact, a benchmark of scientific excellence.
A Professor of Immunology at the University of Murcia and Deputy Scientific Director of IMIB, Dr. Pelegrín is one of the leading international experts in inflammasome research, particularly the NLRP3 complex, the central axis of our VIVA-ELISA® technology. His trajectory has been instrumental in understanding how inflammation drives the progression of multiple diseases and how these mechanisms can be translated into innovative clinical solutions.
His work has produced discoveries of exceptional scientific relevance, including:
- the characterization of pyroptosis, a form of inflammatory programmed cell death;
- the identification of extracellular inflammasomes as immune danger signals;
- and the development of NLRP3 inhibitors, essential in chronic inflammatory diseases.
Beyond his scientific output —over 150 publications, more than 13,000 citations, and over €11 million in competitive European funding (ERC, EIC and H2020)— Dr. Pelegrín has been a driving force in the transfer of knowledge to society as co-founder of Viva In Vitro Diagnostics, an IMIB spin-off and a European reference in precision medicine applied to inflammation and sepsis.
Recognition for Spanish science
This milestone comes in a particularly significant year for Spanish science: 94 national researchers have been included in the Clarivate 2025 list, out of 7,131 recognitions worldwide, highlighting the growing contribution of Spanish research to the global scientific landscape.
At Viva In Vitro Diagnostics, this achievement reinforces the strength of our project and the scientific vision that guides us:
Bringing cutting-edge discoveries in inflammation and immune response into clinical practice to transform the diagnosis and early stratification of critically ill patients.
We continue advancing towards a new generation of clinical tools based on immunological precision, guided by scientific excellence and by a real impact on people’s health.